Research graph
References from Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO). Local targets link to admitted publications; unresolved targets remain external evidence.
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
10.1016/j.radonc.2009.04.014 · 2009 · External reference
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer
10.1200/jco.2003.01.008 · 2003 · External reference
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck
10.1056/nejmoa032646 · 2004 · External reference
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
10.1056/nejmoa032641 · 2004 · External reference
Evaluation of early and late toxicities in chemoradiation trials
10.1200/jco.2007.13.3983 · 2007 · External reference
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
10.1056/nejmoa053422 · 2006 · External reference
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
10.1200/jco.2006.08.8005 · 2007 · External reference
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
10.1016/s1470-2045(09)70311-0 · 2010 · External reference
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
10.1016/s1470-2045(14)71198-2 · 2015 · External reference
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial
10.1016/s1470-2045(14)71200-8 · 2015 · External reference
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
10.1016/s1470-2045(13)70181-5 · 2013 · External reference
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
10.1016/s1470-2045(11)70034-1 · 2011 · External reference
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522
10.1200/jco.2013.53.5633 · 2014 · External reference
Combining cetuximab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: is more better?
10.1200/jco.2014.56.1902 · 2014 · External reference
FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
10.1007/s00262-008-0613-3 · 2009 · External reference
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
10.1007/s00262-009-0697-4 · 2009 · External reference
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
10.1200/jco.2009.27.6360 · 2010 · External reference
Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck
2017 · External reference
Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
10.1007/s12026-011-8231-0 · 2011 · External reference
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy
10.1007/s00262-017-1960-8 · 2017 · External reference
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
10.1002/cncr.28380 · 2014 · External reference
Immunology and immunotherapy of head and neck cancer
10.1200/jco.2015.61.1509 · 2015 · External reference
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
10.1056/nejmoa1602252 · 2016 · External reference
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
2016 · External reference
Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
10.1093/annonc/mdx374 · 2017 · External reference
Refining American joint committee on cancer/union for international cancer control TNM stage and prognostic groups for human papillomavirus – related oropharyngeal carcinomas
10.1200/jco.2014.58.6412 · 2015 · External reference
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity
10.1200/jco.2014.55.3925 · 2014 · External reference
Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer
10.1158/0008-5472.can-15-2001 · 2016 · External reference
Reversing EGFR mediated immunoescape by targeted monoclonal antibody therapy
10.3389/fphar.2017.00332 · 2017 · External reference
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
10.1158/2159-8290.cd-13-0310 · 2013 · External reference
Increased PD-1 þ and TIM-3 þ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients
10.1158/2326-6066.cir-16-0333 · 2017 · External reference
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
10.1016/s1470-2045(15)00007-8 · 2015 · External reference
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade
10.1158/0008-5472.can-14-1258 · 2014 · External reference
CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer
10.1158/1078-0432.ccr-16-0879 · 2017 · External reference
Irradiation and anti – PD-L1 treatment synergistically promote antitumor immunity in mice
10.1172/jci67313 · 2014 · External reference
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
10.1038/bjc.2016.166 · 2016 · External reference
Stereotactic radiation therapy augments antigen-specific PD-1 mediated anti-tumor immune responses via cross-presentation of tumor antigen
10.1158/2326-6066.cir-14-0196 · 2015 · External reference
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
2016 · External reference
10.1200/jco.2017.35.15_suppl.6011
10.1200/jco.2017.35.15_suppl.6011 · External reference
